Additional cytogenetic changes an predict unfavorable prognosis in and acute myelold leukemia previous genotoxic exposure myelodysplastic syndromes with der(1;7)(q10;p10)

被引:14
|
作者
Hsiao, HH
Sashida, G
Ito, Y
Kodama, A
Fukutake, K
Ohyashiki, JH
Ohyashiki, K
机构
[1] Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, Tokyo 1600023, Japan
[2] Tokyo Med Univ, Cent Lab, Chromosome Unit, Shinjuku Ku, Tokyo 1600023, Japan
[3] Tokyo Med Univ, Intractable Immune Syst Res Ctr, Shinjuku Ku, Tokyo 1600023, Japan
[4] Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung 807, Taiwan
关键词
D O I
10.1016/j.cancergencyto.2005.09.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We analyzed 23 patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) showing a der(1;7)(q10;p10) [hereafter der(1;7)] to identify the exact predictive factor of this cytogenetic change. Eight (34.8%) patients, including six with MDS and two with AML patients, had a previous history of genotoxic exposure, especially radiation and/or antimetabolites. Patients with der(1;7) consisted of three groups: one third of patients had a previous history of genotoxic agents, one third had additional cytogenetic changes at the time of MDS/AML diagnosis without previous exposure history, and the remaining one third had neither a previous exposure history nor additional cytogenetic changes. The current study demonstrated that the poor outcome of MDS/AML with der(1;7) is Caused by the high frequency of associated risk factors (i.e., previous history of genotoxic exposure, the presence of additional cytogenetic changes, or both). Identification of prognostic disadvantage might be required for applying the appropriate strategy in managing MDS/AML patients with rare der(1;7) abnormality. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:161 / 166
页数:6
相关论文
共 50 条
  • [1] Additional cytogenetic changes and prior genotoxic exposure predict unfavorable prognosis in myelodysplastic syndromes and acute myeloid leukemia with der(1;7)(q10;p10).
    Ohyashiki, K
    Hsiao, HH
    Sashida, G
    Ito, Y
    Ohyashiki, JH
    BLOOD, 2005, 106 (11) : 304B - 304B
  • [2] Final clarification of intermediate prognosis of der(1;7) (q10;p10) in an international cohort of myelodysplastic syndromes
    Ganster, C.
    Mueller-Thomas, C.
    Haferlach, C.
    Strupp, C.
    Ogata, K.
    Germing, U.
    Hildebrandt, B.
    Mallo, M.
    Luebbert, M.
    Mueller, C.
    Sole, F.
    Goetze, K. S.
    Vandenberghe, P.
    Goehring, G.
    Steinmetz, T.
    Kroeger, N.
    Platzbecker, U.
    Soeling, U.
    Raynaud, S.
    Shirneshan, K.
    Schanz, J.
    Haase, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 97 - 98
  • [3] Unbalanced translocation der(1;7)(q10;p10) as a distinct subtype in myelodysplastic syndromes
    Okuda, Rurika
    Ochi, Yotaro
    Chonabayashi, Kazuhisa
    Sanada, Masashi
    Handa, Hiroshi
    Shiraishi, Yuichi
    Chiba, Shigeru
    Ishikawa, Takayuki
    Ohyashiki, Kazuma
    Atsuta, Yoshiko
    Miyano, Satoru
    Makishima, Hideki
    Nannya, Yasuhito
    Ogawa, Seishi
    CANCER SCIENCE, 2023, 114 : 797 - 797
  • [4] ETNK1 mutations defines a subclass of der(1;7)(q10;p10) in myelodysplastic syndromes
    Okuda, Rurika
    Nannya, Yasuhito
    Ochi, Yotaro
    Chonabayashi, Kazuhisa
    Makishima, Hideki
    Nagata, Yasunobu
    Sanada, Masashi
    Shiraishi, Yuichi
    Miyano, Satoru
    Atsuta, Yoshiko
    Kasahara, Senji
    Handa, Hiroshi
    Chiba, Shigeru
    Ohyashiki, Kazuma
    Ogawa, Seishi
    CANCER SCIENCE, 2022, 113 : 824 - 824
  • [5] Favorable prognostic phenotype in myelodysplastic syndrome with der(1;7)(q10;p10)
    Horio, Tomohiro
    Enomoto, Megumi
    Watarai, Masaya
    Nakano, Yuuta
    Yamada, Saki
    Matsumura, Saori
    Kanasugi, Jo
    Takasugi, Soichi
    Nakamura, Ayano
    Uchino, Kaori
    Mizuno, Shohei
    Murakami, Satsuki
    Yamamoto, Hidesuke
    Hanamura, Ichiro
    Takami, Akiyoshi
    EJHAEM, 2020, 1 (02): : 558 - 562
  • [6] The t(1;7)(q10;p10) in myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD)
    Hoyer, JD
    Dewald, GW
    Hanson, CA
    MODERN PATHOLOGY, 1998, 11 (01) : 131A - 131A
  • [7] Myeloid neoplasms with der(1;7)(q10;p10)
    Okuda, Rurika
    Ochi, Yotaro
    Saiki, Ryunosuke
    Nakagawa, Masahiro M.
    Goto, Akihiko
    Atsuta, Yoshiko
    Shiraishi, Yuichi
    Mitani, Kinuko
    Chiba, Shigeru
    Takaori, Akifumi
    Miyano, Satoru
    Makishima, Hideki
    Nannya, Yasuhito
    Ogawa, Seishi
    CANCER SCIENCE, 2025, 116 : 122 - 122
  • [8] De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia
    Hsiao, HH
    Ito, Y
    Sashida, G
    Ohyashiki, JH
    Ohyashiki, K
    LEUKEMIA RESEARCH, 2005, 29 (11) : 1247 - 1252
  • [9] Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes
    Ganster, Christina
    Mueller-Thomas, Catharina
    Haferlach, Claudia
    Strupp, Corinna
    Ogata, Kiyoyuki
    Germing, Ulrich
    Hildebrandt, Barbara
    Mallo, Mar
    Luebbert, Michael
    Mueller, Christel
    Sole, Francesc
    Goetze, Katharina S.
    Vandenberghe, Peter
    Goehring, Gudrun
    Steinmetz, Tilman
    Kroeger, Nicolaus
    Platzbecker, Uwe
    Soeling, Ulrike
    Raynaud, Sophie
    Shirneshan, Katayoon
    Schanz, Julie
    Haase, Detlef
    GENES CHROMOSOMES & CANCER, 2019, 58 (10): : 689 - 697
  • [10] Chronic eosinophilic leukemia with 46,XY,1,der(1;7)(q10;p10) translocation
    Chi Young Park
    Choon Hae Chung
    Young Jin Park
    Annals of Hematology, 2004, 83 : 547 - 548